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Abstract
Background: Hemophagocytic lymphohistiocytosis is becoming an increasingly recognized disorder in adults.
Classical Hodgkin lymphoma is a relatively uncommon etiology of hemophagocytic lymphohistiocytosis and may
complicate treatment options. Rituximab, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin are
discussed here as a treatment regimen.
Case presentation: A 66-year-old Hispanic man previously in good health presented with a 1-month history of
recurrent fevers, chills, and night sweats and a 3-week history of new onset jaundice. A bone marrow biopsy revealed a
normocellular bone marrow with increased histiocytes with areas of hemophagocytic activity. He met five out of eight
criteria for hemophagocytic lymphohistiocytosis diagnosis including fevers, pancytopenia, hemophagocytosis, ferritin of
23,292 ng/mL (>500 ng/mL), and soluble-CD25 of 15,330 pg/mL (>1033 pg/mL). A right cervical lymph node biopsy
revealed CD15, CD30, MUM-1, and Epstein–Barr virus-encoded small ribonucleic acid-positive cells with morphologic
findings of classical Hodgkin lymphoma, lymphocyte-rich subtype. He completed 2 weeks of hemophagocytic
lymphohistiocytosis-directed therapy with etoposide and dexamethasone, but then was switched to rituximab,
etoposide, methylprednisolone, high-dose cytarabine, and cisplatin due to minimal improvement in his pancytopenia
and hepatic impairment. He completed one full cycle of rituximab, etoposide, methylprednisolone, high-dose
cytarabine, and cisplatin with notable improvement in serial hepatic function panels and had an undetectable Epstein–
Barr virus viral load. However, he eventually died due to complications of Enterococcus faecalis bacteremia and colonic
microperforation in the setting of persistent pancytopenia.
Conclusions: This case discusses the challenges facing treatment of adult malignancy-associated hemophagocytic
lymphohistiocytosis. Rituximab, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin may be a viable
option for patients with secondary hemophagocytic lymphohistiocytosis and Hodgkin lymphoma who cannot tolerate
standard therapies due to hepatic impairment. Targeted therapy and immunotherapy are promising new areas of
developing treatments.
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Background
Hemophagocytic lymphohistiocytosis (HLH) is a rare life-
threatening disorder that is often difficult to diagnose in the
adult population. Characterized by a diffuse inflammatory
state with a wide variety of clinical presentations, HLH is
usually a delayed diagnosis [1]. This leads to an unfortunate
delay in therapy in a disease with a rapid course and high
mortality. To further complicate matters, current guidelines
stem from the HLH-2004 protocol, which was derived from
trials involving pediatric patients [2].
In contrast to pediatric HLH, adult HLH is more com-
monly secondary in nature and often therapy directed at
treating HLH alone is insufficient. This is quite notable in
the cases of malignancy-driven HLH. To complicate
matters further, the progression of HLH itself can lead to
hepatic dysfunction, making clinicians hesitate to use
cytotoxic chemotherapy directed towards underlying ma-
lignancies. In these cases, the initial use of HLH-directed
therapy in the form of dose-reduced etoposide and dexa-
methasone alone may not lead to effective recovery.
We discuss a case of secondary HLH with Epstein–Barr
virus (EBV)-positive classical Hodgkin lymphoma.
Hodgkin lymphoma can be reported in up to 10% of
malignancy-associated HLH cases and there is a paucity of
data to support an optimal chemotherapy regimen, espe-
cially in light of the dismal survival rates [3, 4]. We de-
scribe an attempt at a novel treatment in the form of
rituximab, etoposide, methylprednisolone, high-dose
cytarabine, and cisplatin (R-ESHAP), a therapy with less
hepatotoxicity, in hopes of targeting the underlying EBV-
positive Hodgkin lymphoma.
Case presentation
A previously healthy 66-year-old Hispanic man pre-
sented with a 1-month history of recurrent fevers, chills,
and night sweats and a 3-week history of new onset
jaundice. His pertinent medical history included local-
ized prostate cancer status post-transurethral resection
of prostate in remission, peptic ulcer disease, benign
prostatic hypertrophy, hypertension, hypothyroidism,
and prior left lower extremity deep vein thrombosis sev-
eral years ago. On physical examination, he was fatigued,
febrile, tachycardic, with diffuse jaundice and mild lower
extremity bilateral pitting edema. Just 6 months prior at
a primary care physician visit, he had grossly normal
laboratory values including complete blood count and
liver function tests. A complete blood count on initial
workup at our institute was significant for white blood
cell count of 2.7×103/μL, platelets of 98×109/L, and
hemoglobin of 8.2 g/dL with a mean corpuscular volume
(MCV) of 78 fL. He had normal electrolytes, but abnor-
mal liver function panel with a total protein of 5.2 g/dL,
albumin of 1.3 g/dL, aspartate aminotransferase (AST)
of 135 units/L, alanine aminotransferase (ALT) of 269
units/L, alkaline phosphatase of 1235 units/L, total bili-
rubin of 4.9 mg/dL, direct bilirubin 4.1 mg/dL, and in-
direct bilirubin 0.8 mg/dL. His international normalized
ratio (INR) was elevated at 1.59. Blood cultures and
urine analysis were unremarkable; a QuantiFERON Gold
test was indeterminate. Further workup for acute liver
failure with abdominal ultrasound, magnetic resonance
cholangiopancreatography (MRCP), and hepatobiliary
scan revealed possible findings of chronic cholecystitis but
no biliary obstruction. He was empirically treated with
ceftriaxone for assumed cholecystitis, but the results of his
liver function panel tests continued to worsen.
With his liver function panel and condition continuing
to worsen, a more extensive autoimmune and infectious
workup for liver failure was performed. A viral hepatitis
panel revealed hepatitis A IgM, hepatitis B surface
antigen and core IgM, and hepatitis C antibody to be
negative. Further viral workup did show EBV IgG,
cytomegalovirus (CMV) IgG, and herpes simplex virus
(HSV) I IgG positivity. His EBV viral load was 55,000
copies/mL. EBV IgM, CMV IgM, human herpes virus-8
(HHV-8), human immunodeficiency virus (HIV), parvo-
virus B-19 IgG/IgM, and HSV I/II IgM were all negative.
An autoimmune workup revealed negative antinuclear
antibody (ANA), rheumatoid factor (RF), antiliver/kid-
ney microsomal antibody, antimitochondrial antibody
(AMA), and anti-smooth muscle antibody (ASMA). His
ceruloplasmin and alpha-1 antitrypsin levels were
normal, and he had a negative human hemochromatosis
gene screening.
On day 7, a bone marrow biopsy was performed which
revealed a normocellular bone marrow (50%) with in-
creased histiocytes with areas of hemophagocytic activity
(Fig. 1). Focally, there were ill-defined granulomas
present that contained few large atypical cells (Fig. 2).
Fig. 1 Hemophagocytic activity was present as evidenced by scattered
histiocytes containing abundant red blood cells on the bone marrow
aspirate. Wright-Giemsa, 1000× oil immersion
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Paraffin immunohistochemistry showed positivity for
small and large cells with CD30 and EBV-encoded small
RNA (EBER), as well as few large cells with MUM-1
(Fig. 3). These findings were most compatible with
atypical immunoblasts in the setting of an EBV infection,
but this would be unusual in an immunocompetent
adult. An additional consideration was the possibility of
subtle involvement by Hodgkin lymphoma. The report
suggested further investigation into a possible occult
lymphoma.
On day 10, he was pre-emptively started on treatment
for HLH per the HLH-94 treatment protocol with eto-
poside (initially at 75% dose reduction due to hepatic
impairment, subsequent graduated increases in dose by
25%) and dexamethasone at 10 mg/m2 daily. This was
continued for a 2-week course. Further laboratory test-
ing revealed that he met five out of eight criteria for
HLH diagnosis: fevers, pancytopenia, hemophagocytosis,
ferritin of 23,292 ng/mL (>500 ng/mL), and soluble-
CD25 of 15,330 pg/mL (>1033 pg/mL). He did not meet
criteria for hypertriglyceridemia (161 mg/dL, less than
265) and hypofibrinogenemia (368 mg/dL, more than
150 mg/dL); natural killer (NK) cell activity was not
tested. A subsequent liver biopsy on day 13 revealed
findings of chronic hepatitis and focal histiocytic prolif-
eration consistent with HLH.
With still no clear identifying etiology for secondary
HLH, underlying malignancy was suspected and a positron
emission tomography (PET) scan was performed. This re-
vealed an enlarged right cervical lymph node measuring up
to 1.7 cm as well as increased metabolic activity noted in
his ascending colon. On day 18, a lymph node biopsy was
performed which histologically revealed CD15, CD30,
MUM-1, and EBER-positive cells with morphologic find-
ings of classical Hodgkin lymphoma, lymphocyte-rich sub-
type (Fig. 4). On day 25, after 2 weeks of HLH-directed
therapy with etoposide and dexamethasone, he had min-
imal improvement in his pancytopenia and hepatic impair-
ment. He was then started on R-ESHAP for concurrent
treatment of HLH with underlying Hodgkin lymphoma. He
completed one full cycle of R-ESHAP (rituximab 375 mg/
m2 day 25, etoposide 40 mg/m2 days 26 to 29, methyl-
prednisolone 500 mg days 26 to 28,cisplatin 25 mg/m2
days 26 to 29, and cytarabine dose reduced to 1000 mg/m2
day 30). Only cytarabine was 50% dose reduced based on
hepatic function. Initially he showed improvement in serial
hepatic function panels. His EBV viral load 4 days after
rituximab therapy (day 29 from diagnosis) was below detect-
able limits. However, his treatment course in the setting of
continued neutropenia was complicated by Enterococcus
Fig. 2 The bone marrow clot section showed focal areas contained
rare large atypical cells (center of image) in a mixed background
consisting of granulomatous inflammation, lymphocytes, eosinophils,
and plasma cells. An atypical mitotic figure is present in the lower
right corner. Hematoxylin and eosin, 400×
Fig. 3 Areas with granulomatous inflammation in the bone marrow
were positive for Epstein–Barr virus-encoded small RNA by in situ
hybridization (200×)
Fig. 4 The subsequent cervical lymph node biopsy shows large Reed–
Sternberg cells and variants in a background of mixed inflammation,
diagnostic of classical Hodgkin lymphoma. Hematoxylin and eosin, 400×
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faecalis bacteremia and colonic microperforation. He was
not deemed to be a surgical candidate and his condition did
not improve on broad spectrum antibiotics. Subsequently,
he was transitioned to comfort measures only and moved to
an in-patient hospice and died.
Discussion
HLH is primarily a pediatric syndrome and babies are
most commonly affected [5]. This form, known as primary
HLH, is usually secondary to genetic abnormalities with
known mutations in perforin 1, UNC13D, syntaxin 11,
syntaxin-binding protein-2, SH2D1A, RAB27A, and XIAP
or a defect on chromosome 9q21.3-22 [6]. It is inherited
in an autosomal recessive pattern in up to 25% of the
familial cases [7].
Primary HLH is a syndrome of immune activation and
Stepp et al. first demonstrated perforin mutations as
plausible etiologies [8]. Further animal studies have
shown increased activation of CD8+ T cells and in-
creased interferon gamma production in mice with per-
forin mutations [9]. In a separate study, gene expression
data suggest that there is a marked imbalance of upregu-
lation of proinflammatory proteins (IL-8, IL-6, CCL3,
and CCL4) and anti-inflammatory proteins (TGF-β, IL-
1RA, TNFAIP3, and IL-10) [10].
Secondary HLH, on the other hand, is less age re-
stricted and is more common in adults. This form of
HLH can be associated with an underlying infection,
malignancy, or autoimmune disorder [11–15]. Malignan-
cies leading to secondary HLH may reflect a similar
paradigm of increased inflammatory cytokines originat-
ing from malignant cells. In our case, the inflammatory
process is assumed to be driven by Hodgkin lymphoma
in addition to EBV-affected T cells. The prognosis for
HLH is poor in general but patients with malignancy-
associated HLH have a markedly worse survival [15]. A
recent Swedish study demonstrated that all the patients
with malignancy-related HLH had died, with a dismal
median survival of 22 days [3]. The most commonly re-
ported malignancies associated with secondary HLH are
non-Hodgkin lymphoma, particularly T-cell, and NK cell
lymphoma, which are both strongly associated with EBV
positivity [16]. Classical Hodgkin lymphoma leading to
HLH is relatively rare. A retrospective review of a multicen-
ter study cited just 17 out of 162 cases of HLH secondary to
Hodgkin lymphoma, and another review of a single-center
study reported only 1 out of 62 cases [17, 18]. Of interest,
the prevalence of EBV positivity in HLH has been reported
as high as 94% in Hodgkin disease compared to the typical
prevalence of 30% [19, 20].
Overall, timeliness is imperative in the management of
HLH. Previous case series report that adults with HLH
carry a 30-day mortality of up to 44% and an overall
mortality of up to 75% [21]. In an attempt to secure
earlier diagnosis, scoring systems such as the HScore
have been used for adult populations [22]. The HScore
offers an estimated numerical probability of secondary
HLH through the use of a cumulative integer score de-
rived from variables including ferritin level, ALT, and de-
gree of cytopenia. The currently accepted diagnostic
criteria from clinical trials HLH-94 and HLH-2004 are
from the pediatric population. With HLH being more
frequently identified in the adult population, the 2004
criteria must be modified to prevent missed diagnoses.
A recent retrospective analysis at University of Texas
MD Anderson Cancer Center analyzing cases of patho-
logically confirmed HLH suggested an 18-point HLH
diagnostic criteria for malignancy-associated HLH [4].
Ongoing clinical trials are underway in continued efforts
to try to achieve early diagnosis [23].
Treatment for HLH with underlying malignancy is two-
pronged: immunosuppression targeting the overt inflam-
mation and cytotoxic chemotherapy targeting the
malignancy. Effective treatment of HLH in our patient
raised significant challenges. The established treatment for
Hodgkin lymphoma in the form of adriamycin, bleomycin,
vinblastine, and dexamethasone (ABVD) chemotherapy is
very effective and has been used for decades with response
rates in excess of 70% even in patients with poor progno-
sis [24]. However, in the case of our patient with under-
lying HLH and a total bilirubin >5 mg/dL, the treatment
options are limited. Cytotoxic chemotherapies such as
adriamycin and vinblastine cannot be safely used with se-
verely impaired liver function. In addition, our patient’s
EBER positivity was also taken into consideration in the
fabrication of a treatment regimen. These challenges in
therapy are common in patients with HLH; it implies that
patients often will need individualized therapies. Our se-
lection of R-ESHAP therapy was made in an attempt to
optimize safety and efficacy.
The role of rituximab in EBV-positive Hodgkin lymph-
oma has shown some early promise. A known phase II
study has demonstrated a significant decrease in plasma
EBV positivity, and there is ongoing interest in the incorp-
oration of rituximab in patients with EBV-positive lymph-
omas leading to HLH [25]. Thus far, there are several case
reports reporting the effectiveness of rituximab in EBV-
related HLH proposing success through limitation of in-
flammatory response from infected B cells [26, 27]. Our
patient’s treatment with rituximab showed a positive effect
with a reduction in his viral load to undetectable ranges.
The selection of ESHAP was primarily due to its known
efficacy as salvage therapy in patients with relapsed Hodg-
kin lymphoma. Promising results were shown in using
ESHAP as a less toxic salvage chemotherapy regimen for
Hodgkin lymphoma [28, 29]. An etoposide-based treat-
ment for secondary HLH from underlying malignancy has
been previously recommended to address the overactive
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immune system [21]. The application of ESHAP to our
patient did show evidence of initial improvement in his
liver disease, but he ultimately succumbed to complica-
tions from chemotherapy.
As for now, cytotoxic chemotherapy remains the main-
stay of treatment for adults with HLH secondary to an
underlying malignancy. However, this is often not well tol-
erated in such a severe state of inflammation and multi-
organ failure. This case highlights a common difficulty
in treating patients with malignancy-associated HLH:
treating HLH versus treating the underlying malig-
nancy. Due to the poor therapeutic response to HLH-
directed therapy in our patient, and the revelation of
an underlying diagnosis, a switch was made from
HLH-directed therapy to Hodgkin lymphoma-targeted
therapy. Subsequently, our patient developed severe
chemotherapy-related complications. Future consider-
ations could be made to target the EBV with weekly
rituximab while continuing etoposide for HLH in
order to investigate if EBV rather than Hodgkin
lymphoma may be driving the inflammatory process.
Fortunately, there is a recent increase in prevalence of
targeted immunotherapy in Hodgkin lymphoma. Bren-
tuximab vedotin is an antibody-drug conjugate targeting
CD30 and is currently US Food and Drug Administra-
tion (FDA) approved for patients with Hodgkin lymph-
oma who are post-autologous hematopoietic stem cell
transplant with high risk for relapse [30]. The emergence
of lenalidomide, an antimetabolite with immunomodulatory
activity, and nivolumab, a programmed cell death protein 1
(PD-1) inhibitor, present as feasible options for relapsed and
refractory Hodgkin lymphoma [31–33]. It may be beneficial
to assess the roles of these drugs as a first-line agent in im-
munocompromised or older patients who are not suitable
candidates for cytotoxic chemotherapy.
The emergence of new drugs may also introduce
promising prospects in the treatment of HLH. Ruxoliti-
nib, a Janus kinase 1/2 (JAK 1/2) inhibitor, was shown to
have good in vivo activity in mouse models with HLH
[34]. A pilot study with this drug in patients with HLH
is already underway (NCT02400463). Other novel agents
in clinical trials include tocilizumab, a monoclonal anti-
body against IL-6 receptor (NCT02007239), low-dose
IL-2 (NCT02569463), and alemtuzumab, a monoclonal
antibody against CD52 in combination with etoposide
and dexamethasone (NCT02385110).
Conclusions
Overall, treatment of HLH continues to be a formidable
challenge. Rare presentations of the disorder such as
underlying Hodgkin lymphoma significantly alter the
clinical course and treatment options. Treatment with
R-ESHAP may be a viable option for patients with sec-
ondary HLH and Hodgkin lymphoma who cannot
tolerate standard therapies due to hepatic impairment.
With improvement in management of both Hodgkin
and non-Hodgkin lymphoma as well as the arrival of tar-
geted agents there may be more viable options that can
be used as first-line therapy. The results of new, early
phase trials including ruxolitinib will hopefully improve
survival for these patients in future.
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